Navigation Links
China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
Date:3/1/2010

SHANGHAI, March 1 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics," "the Company") (Nasdaq: CHBT), the leading developer, manufacturer and distributor of probiotics products in China, today announced that that it has appointed Grayling to develop and implement a comprehensive communications program to strategically position and raise the visibility of the Company's growth story, and explain its financial performance to shareholders, potential investors and the financial media.

Jinan Song, Chairman and Chief Executive Officer of China-Biotics, commented, "As China-Biotics is upgrading its production capabilities and expanding its customer portfolio, we are pleased to have Grayling help us create greater global awareness of our competitive advantages and strong growth prospects in the expanding probiotics market."

Grayling, a subsidiary of Huntsworth plc (LSE: HNT), is headquartered in London, and it has merged with sister companies Trimedia and Mmd to create a new global Investor Relations, Public Relations, Public Affairs and Events consultancy. The new company has a global footprint with offices in 70 locations in 40 countries across Europe, the US, the Middle East and Asia Pacific. Grayling is the second largest independent PR firm in the world. http://www.grayling.com .

About China-Biotics

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company develops and produces its proprietary product portfolio including live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 15 and elsewhere in the Company's 2009 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward- looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

    For more information, please contact:

     Travis Cai
     Chief Financial Officer
     China-Biotics, Inc.
     Email: traviscai@chn-biotics.com

     Kevin Theiss
     Grayling
     Tel:   +1-646-284-9409
     Email: kevin.theiss@grayling.com

SOURCE China-Biotics, Inc.

Back to top

RELATED LINKS
http://www.chn-biotics.com

'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
5. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
6. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. China-Biotics, Inc. Completes Foundation for Its New Plant
9. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
10. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
11. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):